Limits...
CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma.

Dai W, Miao H, Fang S, Fang T, Chen N, Li M - Mol Med Rep (2016)

Bottom Line: The CDKN3 expression level was significantly decreased in HCC tumor tissues compared with normal liver tissue and liver cirrhosis tissue.Inhibition of CKDN3 promoted the clonogenic capacity and chemotherapeutic tolerance in HCC tissues compared with controls.Knockdown of CDKN3 resulted in downregulation of p53 and p21 protein levels, whereas, AKT serine/threonine kinase 1 expression was upregulated.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatobiliary Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China.

ABSTRACT
Aberrant expression of CDKN3 may be involved in carcinogenesis of liver cancer. The effect of CDKN3 on tumorigenesis and the molecular mechanisms involved have not been fully elucidated. Immunohistochemistry was performed to detect CDKN3 expression levels in tumor tissues. CDKN3 siRNA was used to knockdown CDKN3 in QGY7701 hepatocellular carcinoma (HCC) cells. Colony formation assay was used to measure the clonogenic capacity of the tumor cells. Cell viability was determined by MTT assay. Logistic regression was performed to analyze the association between CDKN3 expression level and the HCC clinical pathology index. The CDKN3 expression level was significantly decreased in HCC tumor tissues compared with normal liver tissue and liver cirrhosis tissue. Additionally, CDKN3 expression was negatively‑associated with the pathological stage of the tumor. Inhibition of CKDN3 promoted the clonogenic capacity and chemotherapeutic tolerance in HCC tissues compared with controls. Knockdown of CDKN3 resulted in downregulation of p53 and p21 protein levels, whereas, AKT serine/threonine kinase 1 expression was upregulated. Thus, CDKN3 expression may reduce the survival of tumor cells and alter the sensitivity to therapeutic agents via the AKT/P53/P21 signaling pathway. Therefore, CDKN3 may be involved in tumor differentiation and self-renewal.

No MeSH data available.


Related in: MedlinePlus

CDKN3 expression is correlated with tumor stage. (A) CDKN3 expression at hepatocellular carcinoma tumor stages I-IV were determined using immunohistochemistry. (B) The association between CDKN3 expression and tumor stage was determined using logistic regression analysis. CDKN3, cyclin-dependent kinase inhibitor 3.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940071&req=5

f2-mmr-14-02-1509: CDKN3 expression is correlated with tumor stage. (A) CDKN3 expression at hepatocellular carcinoma tumor stages I-IV were determined using immunohistochemistry. (B) The association between CDKN3 expression and tumor stage was determined using logistic regression analysis. CDKN3, cyclin-dependent kinase inhibitor 3.

Mentions: Tumor pathological stage was evaluated according to the cell nuclear morphology and the karyoplasmic ratio. This is a vital factor for cancer prognosis. A tumor at a high stage is associated with poor prognosis. The HCC tumor stage was evaluated and the association between CDKN3 expression and tumor stages was analyzed (Fig. 2A). It was determined that CDKN3 is negatively associated with tumor stage (Fig. 2B; P<0.00026). Thus, CDKN3 expression levels were downregulated in high stage cancer with immature tumor cells.


CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma.

Dai W, Miao H, Fang S, Fang T, Chen N, Li M - Mol Med Rep (2016)

CDKN3 expression is correlated with tumor stage. (A) CDKN3 expression at hepatocellular carcinoma tumor stages I-IV were determined using immunohistochemistry. (B) The association between CDKN3 expression and tumor stage was determined using logistic regression analysis. CDKN3, cyclin-dependent kinase inhibitor 3.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940071&req=5

f2-mmr-14-02-1509: CDKN3 expression is correlated with tumor stage. (A) CDKN3 expression at hepatocellular carcinoma tumor stages I-IV were determined using immunohistochemistry. (B) The association between CDKN3 expression and tumor stage was determined using logistic regression analysis. CDKN3, cyclin-dependent kinase inhibitor 3.
Mentions: Tumor pathological stage was evaluated according to the cell nuclear morphology and the karyoplasmic ratio. This is a vital factor for cancer prognosis. A tumor at a high stage is associated with poor prognosis. The HCC tumor stage was evaluated and the association between CDKN3 expression and tumor stages was analyzed (Fig. 2A). It was determined that CDKN3 is negatively associated with tumor stage (Fig. 2B; P<0.00026). Thus, CDKN3 expression levels were downregulated in high stage cancer with immature tumor cells.

Bottom Line: The CDKN3 expression level was significantly decreased in HCC tumor tissues compared with normal liver tissue and liver cirrhosis tissue.Inhibition of CKDN3 promoted the clonogenic capacity and chemotherapeutic tolerance in HCC tissues compared with controls.Knockdown of CDKN3 resulted in downregulation of p53 and p21 protein levels, whereas, AKT serine/threonine kinase 1 expression was upregulated.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatobiliary Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China.

ABSTRACT
Aberrant expression of CDKN3 may be involved in carcinogenesis of liver cancer. The effect of CDKN3 on tumorigenesis and the molecular mechanisms involved have not been fully elucidated. Immunohistochemistry was performed to detect CDKN3 expression levels in tumor tissues. CDKN3 siRNA was used to knockdown CDKN3 in QGY7701 hepatocellular carcinoma (HCC) cells. Colony formation assay was used to measure the clonogenic capacity of the tumor cells. Cell viability was determined by MTT assay. Logistic regression was performed to analyze the association between CDKN3 expression level and the HCC clinical pathology index. The CDKN3 expression level was significantly decreased in HCC tumor tissues compared with normal liver tissue and liver cirrhosis tissue. Additionally, CDKN3 expression was negatively‑associated with the pathological stage of the tumor. Inhibition of CKDN3 promoted the clonogenic capacity and chemotherapeutic tolerance in HCC tissues compared with controls. Knockdown of CDKN3 resulted in downregulation of p53 and p21 protein levels, whereas, AKT serine/threonine kinase 1 expression was upregulated. Thus, CDKN3 expression may reduce the survival of tumor cells and alter the sensitivity to therapeutic agents via the AKT/P53/P21 signaling pathway. Therefore, CDKN3 may be involved in tumor differentiation and self-renewal.

No MeSH data available.


Related in: MedlinePlus